This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Asa, S. L. Articles by Ezzat, S. Search for Related Content PubMed PubMed Citation Articles by Asa, S. L. Articles by Ezzat, S.

A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors

¹ Department of Pathology, University Health Network and Toronto Medical Laboratories, and ² Department of Medicine, Mount Sinai Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada; ³ Endocrinology Section Medical Service, Veterans Affairs Medical Center and Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; ⁴ Department of Neurosurgery, Toranomon Hospital, Tokyo, Japan; and ⁵ Department of Pathology, Tokushima University, Tokushima, Japan

Requests for reprints: Sylvia L. Asa, Ontario Cancer Institute-University of Toronto, 610 University Avenue 8-209, Toronto, Ontario, Canada M5G 2M95. Phone: 416-946-2099; Fax: 416-340-5517; E-mail: sylvia.asa{at}uhn.on.ca.

Pituitary tumors are a diverse group of neoplasms that are classified based on clinical manifestations, hormone excess, and histomorphologic features. Those that cause growth hormone (GH) excess and acromegaly are subdivided into morphologic variants that have not yet been shown to have pathogenetic significance or predictive value for therapy and outcome. Here, we identify a selective somatic histidine-to-leucine substitution in codon 49 of the extracellular domain of the GH receptor (GHR) in a morphologic subtype of human GH-producing pituitary tumors that is characterized by the presence of cytoskeletal aggresomes. This GHR mutation significantly impairs glycosylation-mediated receptor processing, maturation, ligand binding, and signaling. Pharmacologic GH antagonism recapitulates the morphologic phenotype of pituitary tumors from which this mutation was identified, inducing the formation of cytoskeletal keratin aggresomes. This novel GHR mutation provides evidence for impaired hormone autofeedback in the pathogenesis of these pituitary tumors. It explains the lack of responsiveness to somatostatin analogue therapy of this tumor type, in contrast to the exquisite sensitivity of tumors that lack aggresomes, and has therapeutic implications for the safety of GH antagonism as a therapeutic modality in acromegaly. [Cancer Res 2007;67(15):7505–11]